Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nerandomilast - Boehringer Ingelheim

Next Previous
Search
Drug Profile

Nerandomilast - Boehringer Ingelheim

Alternative Names: BI-1015550

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class 2 ring heterocyclic compounds; Alcohols; Amines; Anti-inflammatories; Antifibrotics; Chlorinated hydrocarbons; Cyclobutanes; Piperidines; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Idiopathic pulmonary fibrosis
  • Phase III Interstitial lung diseases
  • Phase II Systemic scleroderma

Most Recent Events

  • 23 Apr 2025 Phase-II clinical trials in Systemic scleroderma (PO) before April 2025 (Boehringer Ingelheim pipeline, April 2025)
  • 08 Apr 2025 Boehringer Ingelheim completes a phase III trial in Interstitial lung diseases in the US, Puerto Rico, Spain, Norway, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Croatia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Sweden, Switzerland, Serbia, Slovenia, Saudi Arabia, Taiwan, Thailand, Turkey, the UK, Czech Republic, Israel and India (PO) (NCT05321082)
  • 02 Apr 2025 Preregistration for Idiopathic pulmonary fibrosis (PO), before April 2025

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top